Abstract: This invention concerns a method for treating or preventing a disease or disorder related to excessive formation of vascular tissue or blood vessels in a patient, said method comprising administering to said patient an agent affecting the NPY Y2 receptor.

Abstract: The invention relates to a DNA sequence comprising a nucleotide sequence encoding a prepro-neuropeptide Y (preproNPY) where the leucine amino acid in position 7 of the signal peptide part of said preproNPY has been replaced by proline. The invention concerns further the mutant signal peptide or the mutant signal peptide associated with any other cleavage product of preproNPY, methods for the determination, in a biological sample, of the DNA sequence or the peptide. Furthermore, this invention relates to a method for diagnosing a predisposition for increased serum cholesterol or LDL cholesterol level in a human subject, and to methods for treating a human subject diagnosed for predisposition for increased serum cholesterol or LDL cholesterol. The present invention also relates to transgenic animals carrying either the mutant sequence or the normal sequence.

Abstract: This invention concerns a method for treating or preventing a disease or disorder related to excessive formation of vascular tissue or blood vessels in a patient, said method comprising administering to said patient an agent affecting the NPY Y2 receptor.

Abstract: The invention relates to methods for diagnosing a person's susceptibility for having an increased risk for the development of atherosclerosis and a diabetic person's susceptibility for having an increased risk for the development of diabetic retinopathy. The invention relates further to methods for treating persons diagnosed for having increased risk for the development of said diseases, in order to prevent the development of said diseases. The invention also concerns methods to investigate or screen pharmaceuticals or genetic aims useful in the treatment of said diseases, by using an animal model including a transgenic animal.

Abstract: This invention relates to method for reducing the overproduction of neuropeptide Y (NPY) in an individual, said method being aimed to modulate an overactive NPY system in said individual. The overproduction is either counteracted by administering an antagonist, or in case the individual has a polymorphism comprising the substitution of the position 7 leucine for proline in the signal peptide part of the preproNPY, said individual is subjected to a method aimed to reduce or prevent expression of the mutated allele causing said polymorphism.

Abstract: This invention concerns a method for treating or preventing a disease or disorder related to excessive formation of vascular tissue or blood vessels in a patient, said method comprising administering to said patient an agent affecting the NPY Y2 receptor.

Abstract: This invention relates to a DNA sequence comprising a nucleotide sequence encoding a variant &agr;2B-adrenoceptor protein and to the variant &agr;2B-adrenoceptor protein as well as a method for screening a subject to determine if the subject is a carrier of a variant gene that encodes the variant &agr;2B-adrenoceptor protein. This invention also relates to a method for treating a mammal suffering from vascular contraction of coronary arteries, the method comprising the step of administering a selective &agr;2B-adrenoceptor antagonist to the mammal. This invention further relates to transgenic animals comprising a human DNA molecule encoding human &agr;2B-adrenoceptor protein or the variant &agr;2B-adrenoceptor protein.

Abstract: This invention relates to a DNA sequence comprising a nucleotide sequence encoding a variant &agr;2B-adrenoceptor protein and to the variant &agr;2B-adrenoceptor protein as well as a method for screening a subject to determine if the subject is a carrier of a variant gene that encodes the variant &agr;2B-adrenoceptor protein. Further this invention relates to a method for treating a mammal suffering from vascular contraction of coronary arteries, the method comprising the step of administering a selective &agr;2B-adrenoceptor antagonist to the mammal and to transgenic animals comprising a human DNA molecule encoding human &agr;2B-adrenoceptor protein or the variant &agr;2B-adrenoceptor protein.

Abstract: This invention concerns a method for treating or preventing a disease or disorder related to excessive formation of vascular tissue or blood vessels in a patient, said method comprising administering to said patient an agent affecting the NPY Y2 receptor.

Abstract: The invention relates to methods for diagnosing a person's susceptibility for having a risk for the development of alcoholism. The invention relates further to methods for treating persons diagnosed for having risk for the development of alcoholism in order to prevent the development of said condition. The invention also concerns methods to investigate or screen pharmaceuticals or genetic aims useful in the treatment of said condition, by using an animal model including a transgenic animal.

Abstract: The invention relates to a DNA sequence comprising a nucleotide sequence encoding a prepro-neuropeptide Y (preproNPY) where the leucine amino acid in position 7 of the signal peptide part of said preproNPY has been replaced by proline. The invention concerns further the mutant signal peptide as such or associated with any other cleavage product of preproNPY, methods for the determination, in a biological sample, of said DNA sequence or said peptide. Furthermore, this invention relates to a method for diagnosing a predisposition for increased serum cholesterol or LDL cholesterol level in a human subject, and to methods for treating a human subject diagnosed for predisposition for increased serum cholesterol or LDL cholesterol. Transgenic animals carrying either the mutant sequence or the normal sequence are also within the scope of this invention.

Abstract: The present invention concerns a method for enhancing the endothelial function in humans, comprising administering to the person an NPY receptor active agent, wherein said receptor is present in the endothelial tissue. Furthermore, the invention concerns methods for the treatment or prevention of atherosclerotic vascular diseases; vascular spasm associated with angina pectoris; micro- or macrovascular complications of diabetes; premature ejaculation and impotence; or any disease or disorder where a deficit in the formation of nitric oxide for the vascular endothelium appears evident, said methods comprising administering to the person an NPY receptor active agent, wherein said receptor is present in the endothelial tissue.

Abstract: The invention relates to methods for diagnosing a person's susceptibility for having an increased risk for the development of atherosclerosis and a diabetic person's susceptibility for having an increased risk for the development of diabetic retinopathy. The invention relates further to methods for treating persons diagnosed for having increased risk for the development of said diseases, in order to prevent the development of said diseases. The invention also concerns methods to investigate or screen pharmaceuticals or genetic aims useful in the treatment of said diseases, by using an animal model including a transgenic animal.

Abstract: This invention relates to a DNA sequence comprising a nucleotide sequence encoding a variant &agr;2B-adrenoceptor protein and to said variant &agr;2B-adrenoceptor protein as well as a method for screening a subject to determine if said subject is a carrier of a variant gene that encodes said variant &agr;2B-adrenoceptor. Further this invention relates to a method for treating a mammal suffering from vascular contraction of coronary arteries, said method comprising the step of administering a selective &agr;2B-adrenoceptor antagonist to said mammal and to transgenic animals comprising a human DNA molecule encoding human &agr;2B-adrenoceptor or said variant &agr;2B-adrenoceptor.

Abstract: The invention relates to a DNA sequence comprising a nucleotide sequence encoding a prepro-neuropeptide Y (PreproNPY) where the leucine amino acid in position 7 of the signal peptide part of said preproNPY has been replaced by proline. The invention concerns further the mutant signal peptide as such or associated with any other cleavage product of preproNPY, methods for the determination, in a biological sample, of said DNA sequence or said peptide. Furthermore, this invention relates to a method for diagnosing a predisposition for increased serum cholesterol or LDL cholesterol level in a human subject, and to methods for treating a human subject diagnosed for predisposition for increased serum cholesterol or LDL cholesterol. Transgenic animals carrying either the mutant sequence or the normal sequence are also within the scope of this invention.

Abstract: An allelic variant of the 5HT7 serotonin receptor was discovered. Family study data indicate that this variant can be correlated to alchoholic offerders. DNA encoding the variant protein, the protein itself, vectors containing the variant gene and cell lines carrying a vector with the variant gene are part of the invention.